ZETAMAST

Serial Number 97741225
Registration 7892487
700

Registration Progress

Application Filed
Jan 4, 2023
Under Examination
Jan 2, 2024
Approved for Publication
Nov 7, 2023
Published for Opposition
Nov 7, 2023
Registered
Aug 12, 2025

Trademark Image

ZETAMAST

Basic Information

Serial Number
97741225
Registration Number
7892487
Filing Date
January 4, 2023
Registration Date
August 12, 2025
Published for Opposition
November 7, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 12, 2025
Registration
Registered
Classes
005

Rights Holder

Zetagen Therapeutics, Inc.

03
Address
841 East Fayette Street
Syracuse, NY 13210

Ownership History

Zetagen Therapeutics, Inc.

Original Applicant
03
Syracuse, NY

Zetagen Therapeutics, Inc.

Owner at Publication
03
Syracuse, NY

Zetagen Therapeutics, Inc.

Original Registrant
03
Syracuse, NY

Legal Representation

Attorney
Katherine P. Califa

Application History

28 events
Date Code Type Description Documents
Sep 15, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 12, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 12, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jul 24, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jul 24, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jul 23, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jul 18, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jul 18, 2025 IUAF S USE AMENDMENT FILED Loading...
Jun 10, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jun 10, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Jun 10, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 6, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 6, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 5, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Nov 18, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 18, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 17, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 17, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 17, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 17, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 2, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 7, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 7, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 18, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 5, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 28, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 9, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 7, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the treatment of tumor and metastatic tumor diseases; pharmaceutical preparations for the treatment of tumor and metastatic tumors and lesions; Pharmaceuticals, namely, for destroying, inhibiting or preventing the spread of uncontrolled growth of abnormal tissues, namely, tumor and metastatic tumors and lesions
First Use Anywhere: Jul 17, 2025
First Use in Commerce: Jul 17, 2025

Classification

International Classes
005